Cargando…

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis

The pathogenesis of SpA is multifactorial and involves a range of immune cell types and cytokines, many of which utilize Janus kinase (JAK) pathways for signaling. In this review, we summarize the animal and pre-clinical data that have demonstrated the effects of JAK blockade on the underlying molec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veale, Douglas J, McGonagle, Dennis, McInnes, Iain B, Krueger, James G, Ritchlin, Christopher T, Elewaut, Dirk, Kanik, Keith S, Hendrikx, Thijs, Berstein, Gabriel, Hodge, Jennifer, Telliez, Jean-Baptiste
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343466/ https://www.ncbi.nlm.nih.gov/pubmed/29618084 http://dx.doi.org/10.1093/rheumatology/key070

Ejemplares similares

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
por: McGonagle, Dennis G, et al.
Publicado: (2019)

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition
por: McInnes, Iain B, et al.
Publicado: (2021)

BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management
por: Marzo-Ortega, Helena, et al.
Publicado: (2020)

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
por: McGonagle, Dennis, et al.
Publicado: (2023)

Cytokine “fine tuning” of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL-17 targeted therapies
por: Russell, Tobias, et al.
Publicado: (2021)

A role for neutrophils in early enthesitis in spondyloarthritis
por: Stavre, Zheni, et al.
Publicado: (2022)

Progress in spondylarthritis. Immunopathogenesis of spondyloarthritis: which cells drive disease?
por: Melis, Lode, et al.
Publicado: (2009)

Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials
por: Mease, Philip J., et al.
Publicado: (2021)

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies
por: McGonagle, Dennis, et al.
Publicado: (2021)

Health-care workers recovered from natural SARS-CoV-2 infection should be exempt from mandatory vaccination edicts
por: McGonagle, Dennis G
Publicado: (2022)

The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights
por: Toussirot, Eric
Publicado: (2022)

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
por: Helliwell, Philip, et al.
Publicado: (2018)

Spondyloarthritis: How far are we from precision medicine?
por: So, Jacqueline, et al.
Publicado: (2022)

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
por: Smolen, Josef S, et al.
Publicado: (2018)

What magnetic resonance imaging has told us about the pathogenesis of rheumatoid arthritis – the first 50 years
por: McGonagle, Dennis, et al.
Publicado: (2008)

Correction: What magnetic resonance imaging has told us about the pathogenesis of rheumatoid arthritis – the first 50 years
por: McGonagle, Dennis, et al.
Publicado: (2009)

A Proposed Classification of the Immunological Diseases
por: McGonagle, Dennis, et al.
Publicado: (2006)

Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis
por: Paroli, Marino, et al.
Publicado: (2023)

Characterization of Blood Mucosal‐Associated Invariant T Cells in Patients With Axial Spondyloarthritis and of Resident Mucosal‐Associated Invariant T Cells From the Axial Entheses of Non‐Axial Spondyloarthritis Control Patients
por: Rosine, Nicolas, et al.
Publicado: (2022)

Inflammatory Foot Involvement in Spondyloarthritis: From Tarsitis to Ankylosing Tarsitis
por: Romero-López, José Pablo, et al.
Publicado: (2021)

The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2013)

Severe COVID-19 as a virus-independent immunothrombotic process – Authors' reply
por: McGonagle, Dennis, et al.
Publicado: (2022)

Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy
por: Elliott, Ashley, et al.
Publicado: (2021)

Levelling the playing field of RMD research across Europe to address patients’ needs: the emerging EULAR Research Centre
por: Reuter, Katja, et al.
Publicado: (2022)

A role for interleukin-1 receptor antagonism in severe COVID-19?
por: Tattersall, Rachel S, et al.
Publicado: (2021)

Immune cartography of macrophage activation syndrome in the COVID-19 era
por: McGonagle, Dennis, et al.
Publicado: (2021)

Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection
por: McGonagle, Dennis, et al.
Publicado: (2021)

The Effects of an Incentive Boost on Response Rates, Fieldwork Effort, and Costs across Two Waves of a Panel Study
por: McGonagle, Katherine A.
Publicado: (2020)

Mechanistic rationales for targeting interleukin-17A in spondyloarthritis
por: Raychaudhuri, Siba P., et al.
Publicado: (2017)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
por: Coates, Laura C., et al.
Publicado: (2019)

From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases
por: Hromadová, Dominika, et al.
Publicado: (2021)

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
por: Dowty, Martin E., et al.
Publicado: (2019)

Intestinal and enthesis innate immunity in early axial spondyloarthropathy
por: Sharif, Kassem, et al.
Publicado: (2020)

Corrigendum to: Intestinal and enthesis innate immunity in early axial spondyloarthropathy
por: Sharif, Kassem, et al.
Publicado: (2020)

Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis
por: McGonagle, Dennis, et al.
Publicado: (2021)

Time to move away from an oxygen-centric model of pulmonary infarction? – Authors' reply
por: McGonagle, Dennis, et al.
Publicado: (2021)

A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe COVID-19
por: McGonagle, Dennis, et al.
Publicado: (2021)

OA21 Are novel anti-IL5 biologics triggering rheumatoid arthritis?
por: Dean, Nathan, et al.
Publicado: (2023)

PW01-007 – Colchicine brand switching in FMF patients
por: Jagger, J, et al.
Publicado: (2013)

Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints
por: Łukasik, Zuzanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_olet6n6sndv3cru9bu4725bh5r